Chemi-Verse™ AKT1 Kinase Assay Kit

Catalog #
82218
$535 *
Size: 96 reactions
Qty
*US Pricing only. For international pricing, please contact your local distributor.
Purchase
Description

The Chemi-Verse™ AKT1 Kinase Assay Kit is designed to measure AKT1 (protein kinase B) kinase activity for screening and profiling applications using ADP-Glo™ as a detection reagent. The assay kit comes in a convenient 96-well format, with enough purified recombinant AKT1 kinase, kinase substrate, ATP, and kinase assay buffer for 100 enzyme reactions.

Synonyms
AKT1, PKBα, PKBalpha, RACalpha, AKT
Product Info
Storage and Usage
Citations
Assay Kit Format
Luminescent
Materials Required But Not Supplied
  • ADP-Glo™ Kinase Assay (Promega #V6930)
  • DTT (Dithiothreitol), 1M, optional
  • Microplate reader capable of reading luminescence
  • Adjustable micropipettor and sterile tips
  • 30°C incubator
Format
Catalog # Name Amount Storage
40003 AKT1, Active* 2.5 µg -80°C
79334 5x Kinase Buffer 1 1.5 ml -20°C
79686 500 µM ATP 50 µl -20°C
  Crosstide (5 mg/ml) 50 µl -20°C
79696 White 96-well plate 1 Room Temp

*The concentration of the protein is lot-specific and will be indicated on the tube.

UniProt #
P31749
Background

AKT1, also known as Protein Kinase B Alpha (PKBα), is a serine/threonine kinase found in various cell types throughout the body, where it plays a critical role in regulating cell survival, insulin signaling, angiogenesis and tumor formation as well as controlling apoptosis. The signaling pathways involving AKT1 kinase are essential for the normal development and function of the nervous system. AKT1 has a broad number of targets and can thus regulate multiple pathways. Dysregulation of AKT1 contributes to a number of serious diseases, including cancer, diabetes, cardiovascular and neurological diseases. In cancer AKT1 is involved in tumor progression and drug resistance. For instance, the activating mutation E17K seems to be present in 7% of the estrogen-receptor positive metastatic breast cancers. The use of AKT inhibitors, such as capivasertib, alone or in combination, is currently under late-stage clinical trials and has been showing great promise for the treatment of cancer patients. A deep understanding of the mechanisms of action of AKT1 and how inhibition of AKT1 can lead to other drug resistance can be crucial to the development of new cancer therapies.

References

Smyth L., et al., 2020 Clin Cancer Res 26(15):3947-3957.
Hua H., et al., 2021 J Hematol Oncol 14:128.